(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Job of a Land Legal counselor in Property Exchanges - 2NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 3Anti-war protests held across Israel under wartime gathering limits
- 4Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
- 510 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- Europe could get 42 more days of summer by the year 2100 due to climate change
- 6 Objections for an Ocean side Wedding
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- What will the Artemis 2 astronauts eat during their historic moon mission? (video)
- In a first, scientists observe a comet reversing its spin
- A top Marine shares his secrets to keeping fit at 50
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
